Skip to main content

Advertisement

SpringerLink
Log in

Anti-Interferon-α-Therapie des systemischen Lupus erythematodes

Anti-interferon alpha therapy of systemic lupus erythematosus

  • Klinische Studien kurzgefasst
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ronnblom L, Alm GV, Eloranta ML (2011) The type I interferon system in the development of lupus. Semin Immunol 23:113–121

    Article  PubMed  Google Scholar 

  2. Bauer JW, Petri M, Batliwalla FM et al (2009) Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 60:3098–3107

    Article  PubMed  CAS  Google Scholar 

  3. Ioannou Y, Isenberg DA (2000) Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy (review). Arthritis Rheum 43:1431–1442

    Article  PubMed  CAS  Google Scholar 

  4. Yao Y, Richman L, Higgs BW et al (2009) Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 60(6):1785–1796

    Article  PubMed  CAS  Google Scholar 

  5. Merrill JT, Wallace DJ, Petri M et al (2011) Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 70:1905–1913

    Article  PubMed  CAS  Google Scholar 

  6. McBride JM, Jiang J, Abbas AR et al (2012) Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 64(11):3666–3676

    Article  PubMed  CAS  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. C. Specker gibt an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Abteilung für Rheumatologie & Klinische Immunologie,Zentrum für Innere Medizin , Kliniken Essen Süd, Propsteistr. 2, 45239, Essen, Deutschland

    C. Specker

Authors
  1. C. Specker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Specker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Specker, C. Anti-Interferon-α-Therapie des systemischen Lupus erythematodes. Z. Rheumatol. 72, 827–829 (2013). https://doi.org/10.1007/s00393-013-1265-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-013-1265-z

Search

Navigation